fluorouracil has been researched along with Neoplasm Metastasis, Unknown Primary in 57 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 9.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 9.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 9.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 7.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 6.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| "The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP)." | 5.22 | A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. ( Bae, WK; Choi, YH; Chung, IJ; Kang, HJ; Kim, BS; Lee, HR; Na, II; Shim, HJ; Shin, DY; Song, EK; Yang, SH; Yuh, YJ, 2016) |
| " Thirty patients with poorly-differentiated carcinoma or poorly-differentiated adenocarcinoma (group A) received a combination of cisplatin and etoposide." | 5.09 | Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. ( Borel, C; Ducreux, M; Fizazi, K; Le Chevalier, T; Ruffié, P; Saghatchian, M; Théodore, C, 2001) |
| "Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primary, and three with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional 5-fluorouracil (FUra) modulated with high-dose leucovorin (LV) and recombinant interferon alpha 2a (IFN-alpha)." | 5.07 | Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. ( Hall, MR; Johnson, PW; Seymour, MT; Slevin, ML; Wrigley, PF, 1994) |
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 5.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 5.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 5.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "At this juncture in the development of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), knowledge about the agent's pharmacologic behavior and clinical antitumor activity in less common neoplasms is being elucidated." | 4.79 | Paclitaxel pharmacology and other tumor types. ( Rowinsky, EK, 1997) |
| "A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum." | 3.79 | [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. ( Baruch-Hennequin, V; Duchemain, B; Duchemann, B; Hennequin, C; Quero, L; Rivera, S; Wong, S, 2013) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 3.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Chemotherapy for squamous cell carcinoma with unknown primary (SCUP) has not been prospectively studied." | 2.68 | Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. ( Allred, C; Anand, V; Khansur, T; Little, D, 1995) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 2.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| " The radiation therapy dosage planned to the whole neck, nasopharynx, and supraclavicular area was 45 Gy in 24 daily fractions in 5 weeks, increasing to 60-70 Gy to the metastatic site." | 2.67 | Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. ( Jeremic, B; Marinkovic, J; Matovic, M; Zivic, DJ, 1993) |
| "Hypotension was observed in three of five patients at the highest dose level (0." | 2.67 | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. ( Botet, J; Crown, J; Gasparetto, C; Gordon, M; Jakubowski, A; Kemeny, N; Meisenberg, B; Sheridan, C; Toner, G; Wong, G, 1991) |
| "A 47-year-old man who was diagnosed as Crohn's disease at the age of 27 became aware of a mass on the forehead." | 2.45 | [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease]. ( Hayashi, N; Hayashi, Y; Hiramatsu, N; Iijima, H; Ito, H; Kondo, J; Nishida, T; Takehara, T; Tsuji, S; Tsujii, M; Tsutsui, S; Yamamoto, K, 2009) |
| "Occult breast cancer presenting with axillary metastases is an unusual presentation and can be a diagnostic and therapeutic challenge." | 2.41 | Occult breast cancer and axillary mass. ( Brenin, DR; Brill, KL, 2001) |
| "Appendix cancer was diagnosed intraoperatively." | 1.42 | [A case of appendix cancer treated as cancer of unknown primary origin]. ( Fujiwara, T; Inada, R; Kishimoto, H; Kondo, Y; Matsumoto, H; Mori, Y; Nagasaka, T; Toshima, T; Watanabe, A; Yagi, T, 2015) |
| "Cases of Sister Mary Joseph's nodule have sporadically been reported." | 1.42 | [Carcinoma of Unknown Primary Associated with a Sister Mary Joseph's Nodule--A Case Report]. ( Hasegawa, H; Kitagawa, Y; Kitasato, K; Kojima, K; Murai, S; Oto, I; Shimizu, H; Yabe, N; Yokose, T; Yoshikawa, T, 2015) |
| "Unknown primary head and neck cancers often require comprehensive mucosal and bilateral neck irradiation." | 1.35 | Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. ( Klem, ML; Kraus, D; Lee, NY; Mechalakos, JG; Pfister, DG; Shah, J; Shaha, A; Singh, B; Wolden, SL; Zelefsky, MJ, 2008) |
| "Unknown primary squamous cell carcinoma in the neck has been treated by combination therapy consisting of chemotherapy, radiation therapy and surgery." | 1.33 | [A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Nakamori, S; Sawamura, T; Tsujinaka, T; Yamashita, S, 2005) |
| "A case of metastatic carcinoid syndrome with hypoxaemia is described." | 1.29 | Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome. ( Bloom, SR; Greaves, JD; Hammond, PJ; Hughes, JM; Hussain, A; Wallis, SC; Young, ET, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (14.04) | 18.7374 |
| 1990's | 17 (29.82) | 18.2507 |
| 2000's | 18 (31.58) | 29.6817 |
| 2010's | 12 (21.05) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Sugarbaker, PH | 1 |
| Hadoux, J | 1 |
| Afchain, P | 1 |
| Walter, T | 1 |
| Tougeron, D | 1 |
| Hautefeuille, V | 1 |
| Monterymard, C | 1 |
| Lorgis, V | 1 |
| Thuillier, F | 1 |
| Baudin, E | 1 |
| Scoazec, JY | 1 |
| Lepage, C | 1 |
| Desgrippes, R | 1 |
| Boilève, A | 1 |
| Wicker, C | 1 |
| Verret, B | 1 |
| Leroy, F | 1 |
| Malka, D | 1 |
| Jozwiak, M | 1 |
| Pontoizeau, C | 1 |
| Ottolenghi, C | 1 |
| De Lonlay, P | 1 |
| Ducreux, M | 2 |
| Hollebecque, A | 1 |
| Matsumoto, H | 1 |
| Inada, R | 1 |
| Nagasaka, T | 1 |
| Watanabe, A | 1 |
| Yagi, T | 1 |
| Toshima, T | 1 |
| Mori, Y | 1 |
| Kondo, Y | 1 |
| Kishimoto, H | 1 |
| Fujiwara, T | 1 |
| Shin, DY | 1 |
| Choi, YH | 1 |
| Lee, HR | 1 |
| Na, II | 1 |
| Yuh, YJ | 1 |
| Kim, BS | 1 |
| Chung, IJ | 1 |
| Bae, WK | 1 |
| Shim, HJ | 1 |
| Song, EK | 1 |
| Yang, SH | 1 |
| Kang, HJ | 1 |
| Yabe, N | 1 |
| Murai, S | 1 |
| Yokose, T | 1 |
| Oto, I | 1 |
| Yoshikawa, T | 1 |
| Kitasato, K | 1 |
| Shimizu, H | 1 |
| Kojima, K | 1 |
| Hasegawa, H | 1 |
| Kitagawa, Y | 1 |
| Hayashi, Y | 1 |
| Nishida, T | 1 |
| Kondo, J | 1 |
| Yamamoto, K | 1 |
| Iijima, H | 1 |
| Tsutsui, S | 1 |
| Hiramatsu, N | 1 |
| Tsujii, M | 1 |
| Tsuji, S | 1 |
| Ito, H | 1 |
| Takehara, T | 1 |
| Hayashi, N | 1 |
| Schuette, K | 1 |
| Folprecht, G | 1 |
| Kretzschmar, A | 1 |
| Link, H | 1 |
| Koehne, CH | 1 |
| Gruenwald, V | 1 |
| Stahl, M | 1 |
| Huebner, G | 1 |
| Kadikoylu, G | 1 |
| Barutca, S | 1 |
| Tataroglu, C | 1 |
| Kafkas, S | 1 |
| Erpek, H | 1 |
| Meydan, N | 1 |
| Yavasoglu, I | 1 |
| Bolaman, Z | 1 |
| Hainsworth, JD | 1 |
| Spigel, DR | 1 |
| Burris, HA | 1 |
| Shipley, D | 1 |
| Farley, C | 1 |
| Macias-Perez, IM | 1 |
| Barton, J | 1 |
| Greco, FA | 1 |
| Møller, AK | 1 |
| Pedersen, KD | 1 |
| Abildgaard, J | 1 |
| Petersen, BL | 1 |
| Daugaard, G | 1 |
| Miura, K | 1 |
| Tsukikawa, S | 1 |
| Nishio, K | 1 |
| Katagiri, H | 1 |
| Sakurai, J | 1 |
| Shimamura, T | 1 |
| Makizumi, R | 1 |
| Otsubo, T | 1 |
| Kusumoto, M | 1 |
| Toyoda, S | 1 |
| Ishikawa, N | 1 |
| Matsumoto, T | 1 |
| Kusumoto, C | 1 |
| Doi, F | 1 |
| Pavlidis, N | 1 |
| Duchemann, B | 1 |
| Duchemain, B | 1 |
| Wong, S | 1 |
| Baruch-Hennequin, V | 1 |
| Rivera, S | 1 |
| Quero, L | 1 |
| Hennequin, C | 1 |
| Gardini, A | 1 |
| Saragoni, L | 1 |
| La Barba, G | 1 |
| Serra, L | 1 |
| Calistri, D | 1 |
| Ulivi, P | 1 |
| Casadei, A | 1 |
| Frassineti, GL | 1 |
| Garcea, D | 1 |
| Assersohn, L | 1 |
| Norman, AR | 1 |
| Cunningham, D | 2 |
| Iveson, T | 1 |
| Seymour, M | 1 |
| Hickish, T | 1 |
| Massey, A | 1 |
| Prior, Y | 1 |
| Hill, ME | 1 |
| JOHNSON, RO | 1 |
| CASTRO, R | 1 |
| ANSFIELD, FJ | 1 |
| Yamashita, S | 1 |
| Hirao, M | 1 |
| Tsujinaka, T | 1 |
| Sawamura, T | 1 |
| Nakamori, S | 1 |
| Mishima, H | 1 |
| Fujitani, K | 1 |
| Ikenaga, M | 1 |
| Kashiwazaki, M | 1 |
| Masuda, N | 1 |
| Spencker, S | 1 |
| Schmittel, A | 1 |
| Westermann, D | 1 |
| Marek, A | 1 |
| Schultheiss, HP | 1 |
| Witzenbichler, B | 1 |
| Schneider, BJ | 1 |
| El-Rayes, B | 1 |
| Muler, JH | 1 |
| Philip, PA | 1 |
| Kalemkerian, GP | 1 |
| Griffith, KA | 1 |
| Zalupski, MM | 1 |
| Kato, S | 2 |
| Yasuda, K | 1 |
| Nishino, Y | 1 |
| Ohori, H | 1 |
| Takahashi, M | 1 |
| Takahashi, S | 1 |
| Yamaura, G | 1 |
| Ohtsuka, K | 1 |
| Kakudo, Y | 1 |
| Chiba, N | 1 |
| Shimodaira, H | 1 |
| Sakayori, M | 1 |
| Suzuki, T | 1 |
| Murakawa, Y | 1 |
| Gamoh, M | 1 |
| Shibata, H | 1 |
| Yoshioka, T | 1 |
| Ishioka, C | 1 |
| Kusaba, H | 1 |
| Shibata, Y | 1 |
| Arita, S | 1 |
| Ariyama, H | 1 |
| Baba, E | 1 |
| Mitsugi, K | 1 |
| Harada, M | 1 |
| Nakano, S | 1 |
| Klem, ML | 1 |
| Mechalakos, JG | 1 |
| Wolden, SL | 1 |
| Zelefsky, MJ | 1 |
| Singh, B | 1 |
| Kraus, D | 1 |
| Shaha, A | 1 |
| Shah, J | 1 |
| Pfister, DG | 1 |
| Lee, NY | 1 |
| Khansur, T | 1 |
| Allred, C | 1 |
| Little, D | 1 |
| Anand, V | 1 |
| Seymour, MT | 1 |
| Johnson, PW | 1 |
| Hall, MR | 1 |
| Wrigley, PF | 1 |
| Slevin, ML | 1 |
| Hussain, A | 1 |
| Young, ET | 1 |
| Greaves, JD | 1 |
| Hammond, PJ | 1 |
| Hughes, JM | 1 |
| Wallis, SC | 1 |
| Bloom, SR | 1 |
| Lenzi, R | 1 |
| Raber, MN | 2 |
| Frost, P | 2 |
| Schmidt, S | 1 |
| Abbruzzese, JL | 2 |
| Jeremic, B | 1 |
| Zivic, DJ | 1 |
| Matovic, M | 1 |
| Marinkovic, J | 1 |
| Nolè, F | 1 |
| Colleoni, M | 1 |
| Buzzoni, R | 1 |
| Bajetta, E | 1 |
| Chen, YM | 1 |
| Whang-Peng, J | 1 |
| Liu, JM | 1 |
| Kuo, BI | 1 |
| Wang, SY | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
| Bonnefoi, H | 1 |
| Smith, IE | 1 |
| Rigg, A | 1 |
| Gore, M | 1 |
| Hill, M | 1 |
| O'Brien, M | 1 |
| Nicolson, M | 1 |
| Chang, J | 1 |
| Watson, M | 1 |
| Norman, A | 1 |
| Hill, A | 1 |
| Oates, J | 1 |
| Moore, H | 1 |
| Ross, P | 1 |
| Rowinsky, EK | 1 |
| Ollivier, S | 1 |
| Fonck, M | 1 |
| Bécouarn, Y | 2 |
| Brunet, R | 2 |
| Lofts, FJ | 1 |
| Gogas, H | 1 |
| Mansi, JL | 1 |
| Serrano-Castro, PJ | 1 |
| Guardado-Santervás, P | 1 |
| Olivares-Romero, J | 1 |
| Parnis, FX | 1 |
| Olver, IN | 1 |
| Kotasek, D | 1 |
| Norman, J | 1 |
| Taylor, A | 1 |
| Russell, J | 1 |
| Patterson, K | 1 |
| Keefe, D | 1 |
| Marafioti, T | 1 |
| Ida, K | 1 |
| Kamiya, T | 1 |
| Dowell, JE | 1 |
| Garrett, AM | 1 |
| Shyr, Y | 1 |
| Johnson, DH | 1 |
| Hande, KR | 1 |
| Saghatchian, M | 1 |
| Fizazi, K | 1 |
| Borel, C | 1 |
| Ruffié, P | 1 |
| Le Chevalier, T | 2 |
| Théodore, C | 1 |
| Karapetis, CS | 1 |
| Yip, D | 1 |
| Virik, K | 1 |
| Strickland, A | 1 |
| Ryder, K | 1 |
| Cowling, M | 1 |
| Harper, PG | 1 |
| Heidemann, J | 1 |
| Gockel, HR | 1 |
| Winde, G | 1 |
| Herbst, H | 1 |
| Domschke, W | 1 |
| Lügering, N | 1 |
| Macdonald, AG | 1 |
| Nicolson, MC | 1 |
| Samuel, LM | 1 |
| Hutcheon, AW | 1 |
| Ahmed, FY | 1 |
| Brill, KL | 1 |
| Brenin, DR | 1 |
| Kelsen, D | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, R | 1 |
| Coit, D | 1 |
| Dave, HP | 1 |
| White, CL | 1 |
| Schulof, R | 1 |
| Avis, FP | 1 |
| Grem, JL | 1 |
| Chu, E | 1 |
| Boarman, D | 1 |
| Balis, FM | 1 |
| Murphy, RF | 1 |
| McAtee, N | 1 |
| Allegra, CJ | 1 |
| Crown, J | 2 |
| Jakubowski, A | 1 |
| Kemeny, N | 1 |
| Gordon, M | 1 |
| Gasparetto, C | 1 |
| Wong, G | 1 |
| Sheridan, C | 1 |
| Toner, G | 1 |
| Meisenberg, B | 1 |
| Botet, J | 1 |
| Faintuch, J | 1 |
| Sumrall, C | 1 |
| Barbé-Gaston, C | 1 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Tremblay, C | 1 |
| Spielman, M | 1 |
| Woolley, PV | 1 |
| Rouesse, J | 1 |
| Sevin, D | 1 |
| Bruckner, HW | 1 |
| McKenna, A | 1 |
| Hart, R | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Yumoto, Y | 1 |
| Okuda, T | 1 |
| Kato, Y | 1 |
| Tashima, M | 1 |
| Sawada, H | 1 |
| Yamagishi, M | 1 |
| Uchino, H | 1 |
| van der Gaast, A | 1 |
| Verweij, J | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Walach, N | 1 |
| Horn, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site[NCT00193609] | Phase 2 | 48 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00193609)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Intervention | 9.7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00193609)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Intervention | 3.7 |
3 reviews available for fluorouracil and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
[Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Fluorouracil; Humans; | 2009 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Occult breast cancer and axillary mass.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Decision Trees; | 2001 |
23 trials available for fluorouracil and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etopos | 2021 |
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2016 |
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2009 |
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2010 |
Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2010 |
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2003 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1994 |
Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 1993 |
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplati | 1997 |
Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dacarbazine; Female; F | 1998 |
Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1999 |
Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubi | 2000 |
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Fema | 2001 |
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differe | 2001 |
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2002 |
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1992 |
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
Topics: Adult; Aged; Blood Glucose; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinati | 1991 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1991 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
31 other studies available for fluorouracil and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorour | 2019 |
[A case of appendix cancer treated as cancer of unknown primary origin].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combi | 2015 |
[Carcinoma of Unknown Primary Associated with a Sister Mary Joseph's Nodule--A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Neop | 2015 |
Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
Topics: Abdomen, Acute; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bio | 2010 |
[A case of unknown primary cancer responding to chemotherapy selected based on the results of an anticancer drug sensitivity test].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Cisplatin; Fluorouracil; Humans; Ma | 2010 |
[A case of multiple para-aortic lymph node metastases from squamous cell carcinoma of an unknown primary responding completely to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Squamous Cell; Cisplatin; Drug Com | 2011 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluoroura | 2012 |
[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report.
Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intr | 2012 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2007 |
Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2007 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome.
Topics: Adult; Carcinoid Tumor; Drug Therapy, Combination; Fluorouracil; Humans; Hypoxia; Liver Neoplasms; L | 1994 |
Serum cytokine level fluctuations in chemotherapy-induced myelosuppression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Carcino | 1996 |
How should cancer presenting as a malignant pleural effusion be managed?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma; Cisplatin; Epi | 1996 |
Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorour | 2000 |
[Induced hypertensive chemotherapy with angiotensin II found effective for mediastinal lymph node metastases of unknown origin].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 2000 |
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2001 |
Signet-ring cell carcinoma of unknown primary location. Metastatic to lower back musculature - remission following FU/FA chemotherapy.
Topics: Abdominal Neoplasms; Aged; Back; Biopsy, Needle; Carcinoma, Signet Ring Cell; Diagnosis, Differentia | 2002 |
Carcinoma of unknown primary site--a complete and sustained response with interleukin-2, alpha interferon and 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Interferon-alpha; Interleukin- | 1992 |
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac | 1992 |
Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fe | 1989 |
Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
[A cancer of unknown primary site with diffuse metastasis to the bone marrow treated effectively with FAM combination chemotherapy].
Topics: Anemia, Myelophthisic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |
Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluo | 1987 |